Novavax, Inc. (NASDAQ:NVAX) Receives Average Recommendation of “Hold” from Brokerages

Shares of Novavax, Inc. (NASDAQ:NVAX) have received a consensus rating of “Hold” from the thirteen ratings firms that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $35.29.

Several equities research analysts recently weighed in on the company. B. Riley set a $35.00 target price on Novavax and gave the company a “buy” rating in a report on Tuesday, September 24th. Citigroup dropped their target price on Novavax from $19.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, September 24th. ValuEngine upgraded Novavax from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. HC Wainwright increased their target price on Novavax from $10.00 to $17.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Finally, Zacks Investment Research cut Novavax from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th.

In other Novavax news, insider Gregory M. Glenn sold 9,620 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $6.18, for a total value of $59,451.60. Following the completion of the sale, the insider now owns 123 shares in the company, valued at approximately $760.14. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO John Trizzino sold 5,578 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $5.72, for a total value of $31,906.16. Following the completion of the sale, the chief financial officer now owns 4,800 shares of the company’s stock, valued at approximately $27,456. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,841 shares of company stock valued at $117,114. Company insiders own 3.30% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP purchased a new stake in Novavax in the 2nd quarter worth approximately $197,000. A.R.T. Advisors LLC purchased a new stake in Novavax in the 2nd quarter worth approximately $435,000. BNP Paribas Arbitrage SA lifted its holdings in Novavax by 7,685.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 79,331 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 78,312 shares during the period. Ontario Teachers Pension Plan Board purchased a new stake in Novavax in the 2nd quarter worth approximately $510,000. Finally, DekaBank Deutsche Girozentrale lifted its holdings in Novavax by 21.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 123,100 shares of the biopharmaceutical company’s stock worth $185,000 after buying an additional 22,000 shares during the period. Institutional investors and hedge funds own 28.19% of the company’s stock.

NVAX stock traded up $0.13 during trading on Monday, hitting $4.69. 360,760 shares of the company traded hands, compared to its average volume of 831,137. The firm has a market capitalization of $110.03 million, a PE ratio of -0.47 and a beta of 2.00. Novavax has a 1 year low of $4.01 and a 1 year high of $51.60. The company has a 50-day moving average of $5.81 and a 200-day moving average of $4.39.

Novavax (NASDAQ:NVAX) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.61) by ($0.08). The company had revenue of $3.36 million during the quarter, compared to the consensus estimate of $3.53 million. During the same period in the previous year, the company earned ($2.40) EPS. As a group, equities analysts predict that Novavax will post -5.53 earnings per share for the current fiscal year.

About Novavax

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

Recommended Story: How does equity income fit into an investing strategy?

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.